CIK 0001833214 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SAB Biotherapeutics, Inc.
Sign in to watch- Ticker
- SABS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 853899721
- Phone
- 305-845-2813
- Business address
- 777 W 41ST ST, SUITE 401, MIAMI BEACH, FL, 33140
- Former names
- Big Cypress Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 16 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-10 | Moin Andrew Director | Grant or award · Preferred Tranche A Warrants | +13,269 | 13,269 | ||
| 2023-11-10 | Moin Andrew Director | Grant or award · Preferred Tranche B Warrants | +8,846 | 20,846 | ||
| 2023-11-10 | Moin Andrew Director | Grant or award · Preferred Tranche C Warrants | +22,115 | 52,115 | ||
| 2023-10-30 | King Michael CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +850,000 | 850,000 | ||
| 2023-10-23 | Sessa Capital (Master), L.P. Director | Grant or award · Series A-1 Convertible Preferred Stock | +16,269 | $1,000.00 | $16.3M | 18,000 |
| 2023-10-23 | Sessa Capital (Master), L.P. Director | Option exercise · Tranche A Warrants | −16,269 | 0 | ||
| 2023-10-23 | Moin Andrew Director | Grant or award · Series A-1 Convertible Preferred Stock | +16,269 | $1,000.00 | $16.3M | 18,000 |
| 2023-10-23 | Moin Andrew Director | Option exercise · Preferred Tranche A Warrants | −16,269 | 0 | ||
| 2023-04-03 | Lucera Erick Director | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-03-14 | Kropotova Alexandra Chief Medical Officer | Grant or award | +275,000 | 275,000 | ||
| 2023-03-14 | Sullivan Eddie Joe Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +525,000 | 525,000 | ||
| 2023-03-14 | Reich Samuel J Executive Chairman | Grant or award · Employee Stock Option (right to buy) | +525,000 | 525,000 | ||
| 2023-03-14 | Bausch Christoph Lawrence Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +275,000 | 275,000 | ||
| 2023-03-14 | Beyer Russell P Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +275,000 | 275,000 | ||
| 2023-02-28 | Spragens Jeffrey G Director | Other acquisition · Warrants | +19,936 | 19,936 | ||
| 2023-02-28 | Reich Samuel J Executive Chairman | Other disposition · Warrants | −208,600 | 0 | ||
| 2023-02-28 | Reich Samuel J Executive Chairman | Other acquisition · Warrants | +9,968 | 9,968 | ||
| 2022-12-07 | HAMILTON CHRISTINE E Director | Grant or award | +82,987 | $1.21 | $100K | 3,111,334 |
| 2022-12-07 | HAMILTON CHRISTINE E Director | Grant or award · Warrant (Common Stock) | +82,987 | 82,987 | ||
| 2022-12-07 | Spragens Jeffrey G Director | Grant or award | +82,987 | $1.21 | $100K | 394,989 |
Page 5 of 9 · 172 trades